Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed small cell lung cancer (SCLC)

Must have received at least one prior course of standard chemotherapy and, if indicated, up to 6,900 cGy of thoracic radiotherapy
Patients who received prior radiotherapy must show evidence of progressive disease
Patients who received no prior radiotherapy to the primary tumor must show evidence of stable or progressive disease
Measurable disease

Must have evidence of carcinoembryonic antigen (CEA) production or expression documented by one of the following:

Serum CEA at least 10 ng/mL
Positive immunohistology of either the primary tumor or a metastasis with CEA specific monoclonal antibody
Must have unilateral bone marrow biopsy with less than 25% tumor involvement
No known, active brain metastases

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

Karnofsky 70-100%
ECOG 0-2

Life expectancy:

At least 3 months

Hematopoietic:

WBC at least 3,000/mm^3
Granulocyte count at least 1,500/mm^3
Platelet count at least 100,000/mm^3

Hepatic:

Bilirubin no greater than 2 mg/dL
AST no greater than 2 times upper limit of normal (ULN)
No hepatitis B or C
No other serious liver abnormality

Renal:

Creatinine no greater than 1.5 times ULN
No urinary incontinence

Cardiovascular:

Ejection fraction at least 50%

Pulmonary:

FEV_1 and FVC at least 60%
DLCO at least 50% predicted

Other:

No severe anorexia, nausea, or vomiting
No other significant medical problems
No prisoners
No reactivity to humanized MN-14 (in patients with prior exposure to chimeric or humanized antibody)
HIV negative
No active HIV-related disease
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for at least 3 months following study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

See Chemotherapy
No concurrent growth factors (e.g., filgrastim [G-CSF])

Chemotherapy:

See Disease Characteristics
At least 4 weeks since prior chemotherapy
No prior high dose chemotherapy with stem cell transplantation

Endocrine therapy:

Not specified

Radiotherapy:

See Disease Characteristics
At least 4 weeks since prior radiotherapy
Prior radiotherapy to less than 30% of red marrow (including standard chest x-ray for limited stage SCLC) allowed

Surgery:

At least 4 weeks since prior major surgery